[Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].
Use and interest of therapeutic association bromocriptine-neuroleptic in schizophrenia. Twelve schizophrenic patients were treated by bromocriptine (7.5 mg.day) and neuroleptic. After one month, patients on this treatment showed a mean improvement of 29% on the total score of the positive and negative symptom scale. This results suggest that therapeutic association bromocriptine-neuroleptic may be used for schizophrenic patients.
Lombertie
E R
ER
Unité de traitement des Psychoses, S.H.U. de Psychiatrie Secteur IV, Limoges.
Durelle
G
G
Fuseau
A
A
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000188:drug therapy; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D001971:Bromocriptine
Utilisation et intérêt de l'association thérapeutique neuroleptique-bromocriptine dans la schizophrénie.